{"id":51672,"date":"2025-12-20T22:10:05","date_gmt":"2025-12-20T14:10:05","guid":{"rendered":"https:\/\/flcube.com\/?p=51672"},"modified":"2026-04-28T12:37:47","modified_gmt":"2026-04-28T04:37:47","slug":"beone-medicines-names-dual-presidents-in-leadership-overhaul","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51672","title":{"rendered":"BeOne Medicines Names Dual Presidents in Leadership Overhaul"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced a leadership restructuring, appointing <strong>Dr. Lai Wang<\/strong> as <strong>President and Global Head of R&amp;D<\/strong>, while <strong>Dr. Xiaobin Wu<\/strong> maintains his role as <strong>President and Chief Operating Officer (COO)<\/strong>. The company will now operate under a <strong>dual\u2011president model<\/strong>, with Dr. Wang overseeing R&amp;D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-executive-appointments\">Executive Appointments<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Role<\/th><th>Executive<\/th><th>Responsibilities<\/th><\/tr><\/thead><tbody><tr><td><strong>President &amp; Global Head of R&amp;D<\/strong><\/td><td>Dr. Lai Wang<\/td><td>R&amp;D, Business Development (BD), Alliance Management<\/td><\/tr><tr><td><strong>President &amp; Chief Operating Officer<\/strong><\/td><td>Dr. Xiaobin Wu<\/td><td>Global commercialization, manufacturing, supply chain (unchanged)<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Dual\u2011President Model<\/td><td>Shared leadership across development and operations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dr. Wang\u2019s Promotion:<\/strong> Previously Global Head of R&amp;D; appointment reflects <strong>BeOne\u2019s emphasis on innovation and pipeline acceleration<\/strong>.<\/li>\n\n\n\n<li><strong>Dr. Wu\u2019s Continuity:<\/strong> Maintains <strong>full P&amp;L responsibility<\/strong> for commercial execution; ensures stability during leadership transition.<\/li>\n\n\n\n<li><strong>Dual\u2011President Model:<\/strong> <strong>Unconventional structure<\/strong> in biotech; enables <strong>specialized focus<\/strong> on discovery vs. commercial execution; may signal <strong>preparation for major partnership or IPO activities<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-organizational-implications\">Market &amp; Organizational Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Impact Area<\/th><th>Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D Pipeline<\/strong><\/td><td>Dr. Wang\u2019s expanded role may <strong>accelerate BD and alliance management<\/strong> for late\u2011stage assets<\/td><\/tr><tr><td><strong>Commercial Execution<\/strong><\/td><td>Dr. Wu\u2019s unchanged responsibilities ensure <strong>continuity in manufacturing scale\u2011up and global launches<\/strong><\/td><\/tr><tr><td><strong>Investor Perception<\/strong><\/td><td>Dual\u2011leadership model demonstrates <strong>depth of executive talent<\/strong>; could attract institutional investors valuing operational clarity<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Structure positions BeOne to compete with larger pharmas in <strong>both innovation and execution<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the dual\u2011president model\u2019s effectiveness, pipeline advancement, and market positioning. Actual results may differ due to integration challenges, competitive dynamics, or leadership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2092,847,3046,848],"class_list":["post-51672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Names Dual Presidents in Leadership Overhaul - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&amp;D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&amp;D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51672\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Names Dual Presidents in Leadership Overhaul\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&amp;D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&amp;D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51672\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-20T14:10:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:37:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Names Dual Presidents in Leadership Overhaul\",\"datePublished\":\"2025-12-20T14:10:05+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1907.webp\",\"keywords\":[\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51672#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51672\",\"name\":\"BeOne Medicines Names Dual Presidents in Leadership Overhaul - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1907.webp\",\"datePublished\":\"2025-12-20T14:10:05+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51672\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1907.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Names Dual Presidents in Leadership Overhaul\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51672#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Names Dual Presidents in Leadership Overhaul\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Names Dual Presidents in Leadership Overhaul - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51672","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Names Dual Presidents in Leadership Overhaul","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.","og_url":"https:\/\/flcube.com\/?p=51672","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-20T14:10:05+00:00","article_modified_time":"2026-04-28T04:37:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51672#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51672"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Names Dual Presidents in Leadership Overhaul","datePublished":"2025-12-20T14:10:05+00:00","dateModified":"2026-04-28T04:37:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51672"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","keywords":["BeOne Medicines","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51672#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51672","url":"https:\/\/flcube.com\/?p=51672","name":"BeOne Medicines Names Dual Presidents in Leadership Overhaul - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51672#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","datePublished":"2025-12-20T14:10:05+00:00","dateModified":"2026-04-28T04:37:47+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai Wang as President and Global Head of R&D, while Dr. Xiaobin Wu maintains his role as President and Chief Operating Officer (COO). The company will now operate under a dual\u2011president model, with Dr. Wang overseeing R&D, Business Development, and Alliance Management, and Dr. Wu continuing to lead global commercialization, manufacturing, and supply chain operations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51672#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51672"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51672#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","width":1080,"height":608,"caption":"BeOne Medicines Names Dual Presidents in Leadership Overhaul"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51672#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Names Dual Presidents in Leadership Overhaul"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51672"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51672\/revisions"}],"predecessor-version":[{"id":51674,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51672\/revisions\/51674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51673"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}